Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis.

Masayuki TanakaYasushi OzekiFujio MatsuyamaTatsunori MurataShinichi ImafukuTaichi Nakamura

Published in: Dermatology and therapy (2021)

These results suggest that apremilast prolongs the time to first biologic therapy use in patients with psoriasis, thereby reducing the total medical cost and decreasing the economic burden on patients.

Keyphrases

rheumatoid arthritis
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
healthcare
patient reported outcomes
bone marrow